Cori Clinical Raises $4M Seed to Speed Up Clinical Trial Design With AI

Cori Clinical, a London startup using AI to improve how clinical trials are designed and set up, has raised $4 million in seed funding led by Breega. Enzo, Heartfelt, Together Ventures and Bynd also took part in the round, Tech.eu reported.

The company is targeting one of the most expensive problems in drug development: trials that are delayed or reworked because of flaws in the original plan.

What Cori Clinical Does

Every clinical trial runs on a protocol, the document that sets out who can take part, what will be measured, how often and for how long. Mistakes or impractical requirements in that document tend to surface only once a trial is under way, when fixing them means a formal amendment, fresh regulatory approvals and months of lost time.

Cori's platform is built to catch those problems earlier. It brings together an organization's own knowledge from previous trials with outside intelligence from regulators, including the FDA in the United States, the MHRA in the United Kingdom and the EMA in Europe, as well as public trial registries.

From that, it creates what the company calls a living blueprint for each trial. Teams can move from an initial brief to a complete protocol and operational plan, while the system flags risks and links design decisions to their effect on budgets and timelines.

Early Results and Customers

Cori estimates its platform can reduce average trial setup costs by 33%. In an internal evaluation, it identified 82% of avoidable protocol errors. Both figures come from the company and have not been independently verified.

Its customer list is notable for a seed-stage business. Cori says it works with two of the world's five largest contract research organizations, the firms that run trials on behalf of drugmakers. It has also supported neurosurgery and neuro-oncology trials at Erasmus MC, the university medical center in Rotterdam.

The Team Behind Cori Clinical

Cori was founded by CEO Jorn Jansen Schoonhoven and CTO Patricio Fernández. Dr. Emma Ogburn has joined as chief clinical officer, adding clinical trial expertise to the leadership team.

"Cori brings that intelligence together into a living blueprint, so teams can make better-informed decisions before avoidable problems become delays, so the science never waits on the process," Jansen Schoonhoven said.

How Cori Clinical Will Use the $4M

The funding will go toward product development, expanding delivery capacity and growing the team across clinical, engineering and commercial roles.

Delivery capacity matters because large research organizations do not adopt new software casually. Each deployment involves integrating with existing processes and earning the trust of teams that work under strict regulatory oversight.

Why the Cori Clinical Funding Matters

Bringing a new drug to market takes years and enormous sums of money, and a large share of both is consumed by clinical trials. Delays have a direct cost: every month a trial slips is a month before patients can access a treatment and before a sponsor can begin to recover its investment.

AI has attracted heavy investment in drug discovery, the search for new molecules. Far less has gone into the operational side of testing them. Cori is betting that better planning, informed by what has gone wrong in past trials, is a faster route to savings than discovery breakthroughs.

With paying customers among the industry's largest research organizations, the company now has to show that its early results hold up across more trials and more therapeutic areas.

Source

Tech.eu — "Cori Clinical secures $4M seed to improve clinical trial design and cut delays"